Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Kymera Therapeutics is viewed favorably because KT-621 could become a first-in-class oral STAT6 degrader with biologic-like efficacy, potentially expanding treatment access across underpenetrated Th2 diseases where Dupixent has only reached about 10% of eligible patients and AD penetration was 18% in early 2026. The accelerated phase 2b atopic dermatitis readout to year-end 2026, with phase 3 initiation by mid-2027, strengthens confidence in a faster, parallel development strategy that could ultimately cover roughly 90% of Dupixent’s revenue opportunity and support >10 phase 3 studies by 2028-29. Financially, the company’s $1.5bn cash balance, low cost of capital, and modelled 2040E risk-adjusted global sales of $7.2bn for KT-621 provide meaningful runway and upside optionality beyond a single indication.

Kymera Therapeutics is viewed negatively because its clinical-stage pipeline remains highly exposed to execution risk, with KT-485 trials in hidradenitis suppurativa and atopic dermatitis potentially difficult to enroll in a timely manner, which can delay development and increase costs. The company also faces meaningful scientific and clinical uncertainty, as unexpected safety concerns in ongoing trials or the failure of promising early data to translate into later-stage success could undermine its STAT6 and IRAK4 programs. In addition, elevated regulatory, competitive, and pricing risk, including pricing reform pressure in the orphan space, adds another layer of fundamental downside.